Clinical Trial Update: Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating crizotinib with etoposide capsule followed by autologous HSCT for relapsed and refractory ALK-positive anaplastic large cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alk-positive Anaplastic Large Cell Lymphoma

Drugs mentioned

• Crizotinib (crizotinib)
• etoposide capsule (etoposide)

Snippet

Sponsor: Mingzhi Zhang | Conditions: ALK-Positive Anaplastic Large Cell Lymphoma | Phase 4 | Status: UNKNOWN